Stock Events

Stock Events

Crescent Biopharma 

$19.32
0
+$4.66+31.79% Thursday 04:00

Statistics

Day High
19.9
Day Low
19.31
52W High
-
52W Low
-
Volume
18
Avg. Volume
-
Mkt Cap
1.86B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30AprExpected
Q3 2025
Q4 2025
Next
-4.01
-2.97
-1.92
-0.88
Expected EPS
-0.878571
Actual EPS
N/A

Financials

11.43%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
211.51MRevenue
24.17MNet Income

Analyst Ratings

$28.50Average Price Target
The highest estimate is 35.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CBIO.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Sangamo Therapeutics works on genomic medicines for genetic diseases, potentially competing in the same therapeutic areas as GlycoMimetics.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is involved in gene editing for genetic diseases, which could compete with GlycoMimetics' drug development programs.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals develops treatments for cystic fibrosis and other serious diseases, competing in the broader market for rare diseases.
Novartis
NVS
Mkt Cap297.32B
Novartis offers a wide range of pharmaceutical products, including treatments for conditions that GlycoMimetics targets.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.67B
BioMarin Pharmaceutical focuses on enzyme replacement therapies for rare genetic disorders, competing in the rare disease space with GlycoMimetics.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.29B
Alnylam Pharmaceuticals specializes in RNAi therapeutics for genetic diseases, potentially competing with GlycoMimetics' therapeutic approaches.
Sarepta Therapeutics
SRPT
Mkt Cap2.44B
Sarepta Therapeutics develops RNA-based therapeutics for rare diseases, which could compete with GlycoMimetics' products.
AMGEN
AMGN
Mkt Cap187.56B
Amgen is a biotechnology company with a broad portfolio, including treatments for conditions that GlycoMimetics may target.

About

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.
Show more...
CEO
ISIN
KYG2545C1042

Listings

F
DE
C68.F
XNAS
US
CBIO
BOATS
BOATS
CBIO.BOATS

0 Comments

Share your thoughts

FAQ

What is Crescent Biopharma stock price today?▼
The current price of CBIO.BOATS is $19.32 USD — it has increased by +31.79% in the past 24 hours. Watch Crescent Biopharma stock price performance more closely on the chart.
What is Crescent Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Crescent Biopharma stocks are traded under the ticker CBIO.BOATS.
What is Crescent Biopharma market cap?▼
Today Crescent Biopharma has the market capitalization of 1.86B
When is the next Crescent Biopharma earnings date?▼
Crescent Biopharma is going to release the next earnings report on April 30, 2026.
What were Crescent Biopharma earnings last quarter?▼
CBIO.BOATS earnings for the last quarter are -4.01 USD per share, whereas the estimation was -2.47 USD resulting in a -62.25% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Crescent Biopharma revenue for the last year?▼
Crescent Biopharma revenue for the last year amounts to 211.51M USD.
What is Crescent Biopharma net income for the last year?▼
CBIO.BOATS net income for the last year is 24.17M USD.
When did Crescent Biopharma complete a stock split?▼
Crescent Biopharma has not had any recent stock splits.